Soon people will be able to subdue a severe allergic reaction with a nasal spray instead of an injection.
On August 9, the U.S. Food and Drug Administration approved the first epinephrine nasal spray for the treatment of severe allergic reactions, including anaphylaxis, in adults and kids who weigh 30 kilograms or more. Called neffy, the spray is expected to be available by early October and to cost $25 with insurance and $199 without for a two-pack, according to ARS Pharmaceuticals, neffy’s maker. The nasal spray device is the same style used for the opioid-reversal medicine Narcan (SN: 12/14/23).